archetype (adl_version=2.3; rm_release=0.0.1)
  SHR-CORE-OncotypeDxDCISRecurrenceScore.oncotype_dx_d_c_i_s_recurrence_score.v0.0.1

specialize
  SHR-CORE-SimplifiedLaboratoryTestResultRecorded.simplified_laboratory_test_result_recorded.v0.0.1

language
  original_language = <[ISO_639-1::en]>

description
  original_author = <
    ["name"] = <"Mark Kramer">
    ["organisation"] = <"The MITRE Corporation">
    ["email"] = <"mkramer@mitre.org">
    ["date"] = <"5/14/2018">
  >
  details = <
    ["en"] = <
      language = <[ISO_639-1::en]>
      purpose = <"SHR implementation of ASCO requirements.">
      use = <"SHR implementation of ASCO requirements.">
      keywords = <"oncology","oncotype dx d c i s recurrence score">
    >
  >
  lifecycle_state = <"initial">
  other_contributors = <"Rute Batiste <rbatiste@mitre.org>, Abhijay Bhatnagar <abhatnagar@mitre.org>, Chris Moesel <cmoesel@mitre.org>, Michael O'Keefe <mokeefe@mitre.org>">
  custodian_organisation = <"The HL7 Cancer Interoperability Group sponsored by Clinical Interoperability Council Work Group (CIC)">
  licence = <"Creative Commons CC-BY <https://creativecommons.org/licenses/by/3.0/>">
  copyright = <"Copyright (c) The MITRE Organization <http://mitre.org>">

definition
  OncotypeDxDCISRecurrenceScore[id1.1.1.1.1.1.1.1] matches {
    /statementTopic matches {
      EvaluationResultTopic[id0.0.0.0.0.0.0.4] matches {
        valueChoiceQuantity matches { Quantity[id0.0.0.0.0.0.0.2] }
        specimen matches { BreastSpecimen[id0.0.0.0.0.0.0.3] }
      }
    }
  }

terminology
  term_definitions = <
    ["en"] = <
      ["id1.1.1.1.1.1.1.1"] = <
        text = <"OncotypeDxDCISRecurrenceScore">
        description = <"The Oncotype DX test for DCIS (Ductal Carcinoma in Situ) breast cancer. Risk scores range from 0 to 100 with the following interpretations: 0-38: Low-Risk, 39-54: Intermediate-Risk, 55+: High-Risk.

                      No LOINC code currently exists for this test. We are seeking feedback on the value of separating OncotypeDx scores for DCIS and invasive breast carcinomas. Does it make more sense to report the OncotypeDx as a single score, regardless of the type of cancer?">
      >
      ["id0.0.0.0.0.0.0.2"] = <
        text = <"Quantity">
        description = <"A quantity with units, whose value may be bounded from above or below, as defined in FHIR.

                      This definition is not fully consistent with CIMI V0.0.4 (whose definition of Quantity lacks a comparator, but includes numerical precision). Complex data types that appear frequently in FHIR have not been profiled, even if CIMI defines them differently. This choice means that the breast cancer profiles use the native FHIR datatype, rather than having to substitute a CIMI profile everywhere the native type is used.">
      >
      ["id0.0.0.0.0.0.0.3"] = <
        text = <"BreastSpecimen">
        description = <"Specimen resulting from biopsy or excision of breast and surrounding tissue.">
      >
      ["id0.0.0.0.0.0.0.4"] = <
        text = <"EvaluationResultTopic">
        description = <"-">
      >
      --["ac0.0.0.0.0.0.0.1"] = <
      --  text = <"http://hl7.org/fhir/us/breastcancer/ValueSet/oncology-OncotypeDxDCISRiskScoreInterpretationVS">
      --  description = <"-">
      -->
      --["at0.0.0.0.0.0.0.1"] = <
      --  text = <"1">
      --  description = <"-">
      -->
      --["at0.0.0.0.0.0.0.2"] = <
      --  text = <"C3898101">
      --  description = <"-">
      -->
      --["at0.0.0.0.0.0.0.3"] = <
      --  text = <"pathology">
      --  description = <"-">
      -->
    >
  >